Granite Investment Partners LLC increased its stake in Trinity Biotech PLC (NASDAQ:TRIB) by 6.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 171,001 shares of the company’s stock after buying an additional 10,239 shares during the period. Granite Investment Partners LLC’s holdings in Trinity Biotech PLC were worth $2,261,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the company. Bank of Montreal Can bought a new stake in Trinity Biotech PLC during the second quarter valued at $8,242,000. Emerald Acquisition Ltd. bought a new stake in Trinity Biotech PLC during the second quarter valued at $5,109,000. DIAM Co. Ltd. increased its stake in Trinity Biotech PLC by 0.6% in the second quarter. DIAM Co. Ltd. now owns 81,300 shares of the company’s stock valued at $922,000 after buying an additional 500 shares in the last quarter. Paradice Investment Management LLC increased its stake in Trinity Biotech PLC by 13.3% in the second quarter. Paradice Investment Management LLC now owns 1,626,496 shares of the company’s stock valued at $18,444,000 after buying an additional 190,772 shares in the last quarter. Finally, Benchmark Capital Advisors increased its stake in Trinity Biotech PLC by 9.0% in the second quarter. Benchmark Capital Advisors now owns 91,041 shares of the company’s stock valued at $1,032,000 after buying an additional 7,500 shares in the last quarter. 70.66% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Trinity Biotech PLC (NASDAQ:TRIB)

Shares of Trinity Biotech PLC (NASDAQ:TRIB) traded down 2.1679% during mid-day trading on Monday, reaching $6.6428. 34,510 shares of the company’s stock traded hands. Trinity Biotech PLC has a one year low of $5.76 and a one year high of $13.68. The firm’s 50-day moving average is $6.77 and its 200 day moving average is $10.56. The firm has a market cap of $151.44 million, a price-to-earnings ratio of 49.9459 and a beta of 1.19.

Trinity Biotech PLC (NASDAQ:TRIB) last issued its quarterly earnings results on Tuesday, October 25th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.07. The business had revenue of $26.10 million for the quarter, compared to analysts’ expectations of $26.50 million. Trinity Biotech PLC had a net margin of 3.04% and a return on equity of 2.73%. Analysts predict that Trinity Biotech PLC will post ($1.67) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this report can be read at https://www.thecerbatgem.com/2016/11/28/trinity-biotech-plc-trib-shares-bought-by-granite-investment-partners-llc.html.

Several analysts have weighed in on TRIB shares. Zacks Investment Research raised shares of Trinity Biotech PLC from a “sell” rating to a “hold” rating in a research report on Saturday, August 20th. Stephens downgraded shares of Trinity Biotech PLC from an “overweight” rating to an “equal weight” rating in a research report on Wednesday, October 5th.

About Trinity Biotech PLC

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

5 Day Chart for NASDAQ:TRIB

Receive News & Stock Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related stocks with our FREE daily email newsletter.